MusclePharm (MusclePharm) Risk Assessment

View and export this data going back to 2008. Start your Free Trial

What is MusclePharm Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of MusclePharm is: No Data: Cannot be evaluated.

Competitive Comparison of MusclePharm's Risk Assessment

For the Packaged Foods subindustry, MusclePharm's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MusclePharm's Risk Assessment Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, MusclePharm's Risk Assessment distribution charts can be found below:

* The bar in red indicates where MusclePharm's Risk Assessment falls into.

MusclePharm (OTCPK:MSLPQ) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

MusclePharm Risk Assessment Related Terms

Thank you for viewing the detailed overview of MusclePharm's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

MusclePharm (MusclePharm) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » MusclePharm Corp (OTCPK:MSLPQ) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

6728 W. Sunset Road, Suite 130, Las Vegas, NV, USA, 89118

Website

https://www.musclepharmcorp.com

MusclePharm Corporation is a performance lifestyle company. It develops, manufactures, markets and distributes branded nutritional supplements. It offers various types of powders, capsules, tablets and gels. Geographically, the firm has its business presence across the region of US and in the international market of which the US accounts for the majority of revenue. MusclePharm's Hybrid series products include Assault, Combat Protein Powder, BCAA 3:1:2, CLA Core, Fish Oil, Combat Crunch Protein Bars, glutamine, carnitine, Combat Crunch, Protein Crisp, Organic Protein, and Protein Cookie. The group sells its products to various fitness enthusiasts, such as professional, combat sport, weight training, bodybuilding, running, and various team and individual sports, and others.

Executives

Eric Chin	officer: Chief Accounting Officer	1668 S. GARFIELD AVE., 2ND FLOOR, ALHAMBRA CA 91801
Paul W Karr	director	BRISTOL MEYERS SQUIBB CO, 345 PARK AVENUE, NEW YORK NY 10154
Sabina Rizvi	officer: President & CFO	6728 W. SUNSET ROAD, SUITE 130, LAS VEGAS NV 89118
Michael David Heller	director	4500 PARK GRANADA, SUITE 202, CALABASAS CA 91302
Wynnefield Partners Small Cap Value Lp I	10 percent owner	450 SEVENTH AVENUE, SUITE 509, NEW YORK NY 10123
Donald Feagan	10 percent owner	2150 SOUTH 1300 EAST STREET, SUITE 500, SALT LAKE CITY UT 84106
Amerop Holdings, Inc.	10 percent owner	1800 BROADWAY, SUITE 100, BOULDER CO 80302
White Winston Select Asset Fund Series Fund Mp-18, Llc	10 percent owner	C/O WHITE WINSTON SELECT ASSET FUNDS, LLC, 265 FRANKLIN ST., SUITE 1702, BOSTON MA 02110
Robert P Mahoney	10 percent owner	4 DANIELS FARM ROAD, #305, TRUMBULL CT 06611
White Winston Select Asset Funds, Llc	10 percent owner	265 FRANKLIN STREET, SUITE 1702, BOSTON MA 02110
Todd M. Enright	10 percent owner	2150 SOUTH 1300 EAST STREET, SUITE 500, SALT LAKE CITY UT 84106
Mark Blundell	10 percent owner	8 MACDONALD AVE, ARMOUK NY 10504
John J Desmond	director	10 GLEN HEAD ROAD, GLEN HEAD NY 11545
Wynnefield Small Cap Value Offshore Fund Ltd	10 percent owner	450 SEVENTH AVE, STE 509, NEW YORK NY 10123
Wynnefield Capital Inc	10 percent owner	450 SEVENTH AVE, STE 509, NEW YORK NY 10123